Life Sciences

  • March 13, 2006

    Boston Scientific Curiously Withdraws Then Refiles

    With the takeover plans moving full steam ahead, medical device maker Boston Scientific Corp. has voluntarily withdrawn and refiled an antitrust notification regarding its $27 billion bid for heart device maker Guidant Corp.

  • March 10, 2006

    Novogen Sues Chattem Over Preventative Health Methods

    Australian biotechnology company Novogen Research Party Ltd. has slammed Chattem Inc. with a lawsuit, accusing the health manufacturer of infringing on a patented method used to treat breast cancer, pre-menstrual syndrome and menopause.

  • March 10, 2006

    Latham & Watkins Scores New Partner

    Hoping to attend to the complex legal needs of the booming biotechnology and life sciences industries in and around Silicon Valley, Latham & Watkins has injected a new key player into its corporate department.

  • March 9, 2006

    Allergan, Alcon Settle Patent Feud Over Eye Drops

    Botox manufacturer Allergan Inc. and Alcon Inc. have amicably ended a patent infringement battle that has lasted nearly two years over Alcon’s brimonidine 0.15% eye drops product.

  • March 8, 2006

    Pfizer Sues Philippines Over Generic Norvasc

    U.S. Pharmaceutical giant Pfizer Inc. is taking on the Philippines to protect patents that cover its second best-selling drug Norvasc, only one month after a sweeping victory in U.S. courts cleared generic opposition.

  • March 9, 2006

    AstraZeneca Starts Patent Squabble With IVAX

    In a move to fend off a rival’s attempts to produce and market a generic form of Nexium, AstraZeneca AB has fired off a lawsuit against drug maker IVAX Corporation for allegedly infringing on patents related to its widely prescribed ulcer drug.

  • March 8, 2006

    Botched Deal Follows AAIPharma's Solvency

    After emerging from Chapter 11 bankruptcy protection, pharmaceutical firm AAIPharma Inc. has hit a roadblock, with the company it sold a major unit to now accusing it in court of failing to follow through on the sale.

  • March 6, 2006

    Roche Wins First Indian Product Patent

    Swiss drug maker F. Hoffmann-La Roche has become the first pharmaceutical company in India to win a product patent under the country’s new patent regime, receiving approval for its hepatitis C drug Pegasys.

  • March 6, 2006

    Bill Would Cut Use Of 30-Month Stay In Drug Suits

    Proposed legislation on Capitol Hill would raise the stakes in disputes between the pharmaceutical industry and generic drug manufacturers, with approval sure to reduce court-approved delays that keep generics off the market while being litigated.

  • March 3, 2006

    E.U. Probes Boston Scientific, Abbott Over Guidant Bids

    The European Commission has initiated an antitrust investigation into medical device maker Boston Scientific Corp.’s $27-billion takeover bid for heart device maker Guidant Corp.

  • March 3, 2006

    Medtronic Pins Infringement Charges on Boston Scientific

    Although Medtronic Vascular, Inc. has been unsuccessful in the past to pin down infringement charges on Boston Scientific Corp., it took another swipe in its latest court filing March 1, hoping that this time the accusations will stick.

  • March 3, 2006

    Federal Circuit Sends Stent Case To Germany

    The U.S. Court of Appeals for the Federal Circuit has ruled that a case over stent patents should have been filed in Germany, upholding a lower court ruling that deflated the suit brought by a doctor against device makers Pfizer and Boston Scientific.

  • March 6, 2006

    Conferences Highlight Foley & Lardner's IP Expertise

    Foley & Larder LLP doesn’t rely on its IP laurels to attract customers and maintain its edge. The firm’s IP practice is highly active in shaping policy and applies significant resources to keep its clients—and industry in general—informed about the latest trends and their potential impact on commerce.

  • March 1, 2006

    Alza Hit With Class Action Lawsuit Over Ditropan XL

    Johnson & Johnson subsidiary Alza Corporation has been smacked with a class-action antitrust lawsuit, accusing the unit of illegally trying to keep generic versions of overactive bladder drug Ditropan XL off the shelf.

  • March 1, 2006

    ABB's Asbestos-Related Reorganization Approved

    In a move that promises to shield ABB Ltd. from future asbestos litigation troubles, a bankruptcy court has approved the amended reorganization plan of the Swiss/Swedish engineering group’s U.S. subsidiary, Combustion Engineering.

  • March 1, 2006

    Sanofi-Aventis Slaps Ranbaxy With Allegra Patent Suit

    Sanofi-Aventis’ battle with generic drug makers over its popular allergy medicine Allegra is raging on, with the French pharmaceutical giant slapping generic manufacturer Ranbaxy with a patent infringement lawsuit.

  • March 1, 2006

    MedImmune Case: Implications For Licensing Agreements

    In agreeing to hear the case between MedImmune and Genentech, the U.S. Supreme Court will set a precedent for whether licensees in good standing are permitted to challenge licensed patents.

  • March 1, 2006

    Metrologic Ordered To Pay $13M Arbitration Award

    A federal judge has ordered barcode equipment maker Metrologic Instruments Inc. to pay a $13.4 million arbitration award to its rival after it allegedly failed to pay royalties on a patent license agreement.

  • March 1, 2006

    AstraZeneca Hit Again With Antitrust Charges

    A government service cooperative has charged AstraZeneca with violating U.S. competition law, the latest swipe in a string of suits filed by nearly a dozen unions, pension funds and government agencies accusing the pharmaceutical giant of illegally trying to prevent generic versions of its blockbuster heart drug, Toprol-XL, from entering the marketplace.

  • February 28, 2006

    Ex-Generic Drug Maker Files Chapter 11 Plan

    Able Laboratories Inc., the former pharmaceutical developer that sold off its assets to India's Sun Pharmaceutical Industries Ltd. last year, is pursuing a Chapter 11 plan designed to pay back unsecured creditors roughly 27% on their claims.